Oramed Pharmaceuticals Inc. (ORMP) Stock

Oramed Pharmaceuticals Inc. (ORMP) is a Healthcare stock trading at $3.88 (as of 2026-06-18), with a market capitalization of $162.48M and a trailing P/E of 1.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Oramed Pharmaceuticals Inc. develops pharmaceutical products including orally delivered capsule and pill formulations intended for diabetes treatment and for delivering polypeptides. Its pipeline includes ORMD-0801 (an oral insulin capsule) and ORMD-0901 (an oral capsule for type 2 diabetes), along with development of an oral leptin capsule for weight loss.

Valuation — source: SEC EDGAR (first-party)
Price$3.88
Market Cap$162.48M
P/E Ratio1.5
EV / EBITDA-17.6
Price / Book0.68
Price / Sales81.24
Dividend Yield6.4%
DCF Value (model)$-2.72
DCF Upside vs Price-170.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.00M
Net Margin3202.5%
Return on Equity46.2%
Debt / Equity0.42
Current Ratio6.45
Financial Health — source: SEC EDGAR
Altman Z-Score2.67 (grey)
Valuation vs Sector & Industry
Stock P/E1.5
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-92.7%
vs Industry-91.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBML Capital Management, LLC ($10.77M)
Institutional Holders Tracked10
Congressional Trades (recent)4
Company
SectorHealthcare
IndustryPharmaceutical Products
CEONadav Kidron
Employees13
CountryUS
IPO Date2007-05-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Inovio Pharmaceuticals, Inc. (INO)
  • Cognition Therapeutics, Inc. (CGTX)
  • Spruce Biosciences, Inc. (SPRB)
  • Fortress Biotech, Inc. (FBIO)
  • Eledon Pharmaceuticals, Inc. (ELDN)
  • Fate Therapeutics, Inc. (FATE)
  • Agenus Inc. (AGEN)
  • Artiva Biotherapeutics, Inc. (ARTV)
ORMP earnings history · ORMP institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.